Work

Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours

Year: 2018

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdy430.002

Authors: D. Tan, M. Ng, V. Subbiah, W. Messersmith, V. Teneggi, V. Diermayr, K. Ethirajulu, P. Yeo, B.H. Gan, L.H. Lee, S. Blanchard, R. Nellore, M. Yasin, D. Umrani, M.A. Lee, J. Hill, B. Madan, D. Virshup, A. Matter

Institutions: National University Cancer Institute, Singapore, National Cancer Centre Singapore, The University of Texas MD Anderson Cancer Center, University of Colorado Denver, Agency for Science, Technology and Research, National University of Singapore, Duke-NUS Medical School

Language: English

Topic: Wnt/β-catenin signaling in development and cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bayer, Loxo Oncology

OpenAlex ID: W2901522674

FWCI: 0.472

Cites:

Cited by: 12

Related to: 10